Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze FATE stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate FATE investment potential.

What is FATE stock price today?

Get real-time FATE stock price, historical data, and price charts on Financhill. Track FATE performance with our advanced analysis tools.

Is FATE a good investment?

Evaluate FATE investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy FATE stock?

To buy FATE stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of FATE?

View detailed market capitalization data and company valuation metrics for FATE on our comprehensive analysis page.

What is the P/E ratio of FATE?

Use our fundamental analysis tools to view FATE P/E ratio and compare valuation metrics with industry peers.

What are FATE earnings?

View FATE earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Fate Therapeutics, Inc. 10K Form

Sell

FATE
Fate Therapeutics, Inc.

Last Price:

$1.08

Seasonality Move:

30.36%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-09	10Q	FATE/Fate Therapeutics, Inc. Quarterly
2023-11-08	10Q	FATE/Fate Therapeutics, Inc. Quarterly
2023-08-08	10Q	FATE/Fate Therapeutics, Inc. Quarterly
2023-05-03	10Q	FATE/Fate Therapeutics, Inc. Quarterly
2022-11-03	10Q	FATE/Fate Therapeutics, Inc. Quarterly
2022-08-03	10Q	FATE/Fate Therapeutics, Inc. Quarterly

Receive FATE News And Ratings

See the #1 stock for the next 7 days that we like better than FATE

FATE Financial Statistics

Sales & Book Value

Annual Sales:	$13.6M
Cash Flow:	$-26.6M
Price / Cash Flow:	0
Annual Sales:	$2.03
Price / Book:	0.53

Profitability

EPS (TTM):	-1.31900
Net Income (TTM):	$-156.1M
Gross Margin:	$-5.3M
Return on Equity:	-53.28%
Return on Assets:	-38.08%

Fate Therapeutics, Inc. Earnings Forecast

Key Fate Therapeutics, Inc. Financial Ratios

The Gross Profit Margin over the past 8 years for FATE is -39.11%.
The Selling, General & Administrative Expenses for FATE have been equal to 544.12% of Gross Profit Margin.
The Research & Development expenses have been 851.29% of Revenue.
The Net Earning history of FATE is -1,366.46% of Total Revenues.
Per Share Earnings over the last 14 years have been positive in 5 years.

Fate Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	FATE
CUSIP:	31189P
Website:	fatetherapeutics.com

Debt

Debt-to-Equity Ratio:	0.34
Current Ratio:	7.87
Quick Ratio:	7.69

Price-to-Earnings

Trailing P/E Ratio:	0
Forward P/E Ratio:	0

FATE Technical Analysis vs Fundamental Analysis